Roche hopes to bolster its capabilities in liver and central nervous system (CNS) disorder gene therapies by turning to Dyno Therapeutics.
Roche made a splash with its acquisition of Spark Therapeutics, whose Luxturna (voretigene neparvovec), a gene therapy for an inherited form of vision loss, was the first such therapy to win FDA approval.
Dyno, a two-year-old startup based in Cambridge, Massachusetts meanwhile, has never brought a gene therapy to the market, nor does it currently have its own drug pipeline. What it does have is a platform technology for engineering the viruses that ferry gene therapies to their cellular targets. Going further, it can design the capsids, the protein shells of these viruses that envelop a gene therapy and deliver it into the cells of a target organ or tissue in the body.
Roche sees enough promise in the Dyno technology to pay the Harvard University spinout a bit of cash now and potentially a lot more later. The companies aren‚Äôt disclosing the amount of the upfront payment or how many therapies are covered under the partnership announced Wednesday. But depending on the progress of the therapies, they say Dyno‚Äôs milestone payments could top $1.8 billion.
Gene therapies that have reached the market so far, such as Luxturna and Zolgensma (onasemnogene abeparvovec), a Novartis treatment for spinal muscular atrophy, are delivered by engineered adeno-associated (AAV) viruses. But AAV capsids, as they‚Äôre found in nature, have limitations, says Eric Kelsic, Dyno‚Äôs CEO. Some of them aren‚Äôt suited for delivery to certain tissues. Others may spark an interaction with the immune system.
There are ways to engineer capsids to make them better suited for a particular cellular target or disease. But Kelsic says improving one property of a capsid can have the effect of altering another one, potentially rendering the capsid ineffective. Dyno aims to improve on capsid design by applying machine-learning techniques and artificial intelligence technology to the process. The biotech automates analysis of data from experiments involving AAV capsids, looking for patterns. The technology screens hundreds of thousands of capsids at one time, looking for desirable properties, such as its ability to target specific tissue, payload capacity, interactions with the immune system, deliverability, and manufacturing. The more data the system analyzes, the better it gets.
‚ÄúEach experiment is learning from everything we‚Äôve done before,‚ÄĚ Kelsic says.
In addition to analyzing how a capsid is delivered to a target cell, the technology also analyzes where else in the body it goes. That information helps Dyno learn about potential off-target effects of the therapy. Dyno calls its technology CapsidMap. Kelsic says the company aims to build an map that shows which capsids are best suited for particular diseases, as well as which capsids are best for addressing particular cells or organs. Dyno was an Xconomy Awards 2020 winner in the ‚ÄúStartup of the Year‚ÄĚ category. Kelsic talks about his company‚Äôs technology in this¬†video¬†(Dyno‚Äôs portion starts at 3:47)
The information provided by Dyno‚Äôs technology guides the company‚Äôs design of a capsid tailor-made for a disease. In CNS disorders, for example, a gene therapy would require a capsid that targets delivery of its genetic payload to neurons, Kelsic says. For liver disorders or disorders that can be addressed by the production of proteins in the liver, a gene therapy would need to target the cells of that organ. More effective and efficient deliverly of a gene therapy to target cells nor only helps patients, it also makes gene therapy production more cost effective.
‚ÄúIf you improve delivery, efficiency, it means you can treat the same patient just as well but at a much lower dose,‚ÄĚ Kelsic says. ‚ÄúIt‚Äôs a safer, better tolerated, potentially longer-lasting therapy. And because it‚Äôs a lower dose, you can treat more patients per batch.‚ÄĚ
Spark Therapeutics‚Äôs Luxturna won FDA approval in 2017. Two years later,¬†Roche acquired Spark for $4.8 billion. In addition to other eye disorders, the Spark pipeline spans liver diseases and CNS disorders. The most advanced Spark program, SPK-8011, is expected to enter Phase III development next year for hemophilia A. The drug is in development under a partnership with Pfizer.
Though the Roche alliance with Dyno calls for the startup to use its technology to design capsids for CNS and liver gene therapies, the companies aren‚Äôt specifying which diseases are covered by the pact. Dyno will use its technology to design capsids and Roche will supply the genetic payloads that they will carry. Roche will handle preclinical and clinical development of the gene therapy candidates, as well as commercialization if they‚Äôre approved.
The structure of the deal is similar to alliances with Novartis and Sarepta Therapeutics that¬†Dyno unveiled in May, when the startup emerged from stealth. The Novartis pact is focused on gene therapies for eye diseases while the Sarepta agreement aims to develop therapies for muscle disorders.
One thing that Dyno does not yet have is an internal pipeline of gene therapy candidates. Kelsic says his company has been focused on building its technology. He won‚Äôt rule out Dyno pursuing its own gene therapies in the future, but he says that the company is also looking for more partners that can help take the company‚Äôs technology to more diseases in more parts of the body.